Related Experiment Video
Updated: Jun 15, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Gene therapy for Parkinson's disease
Tomas Bjorklund1, Jeffrey H Kordower
1Brain Repair and Imaging in Neural Systems, Department of Experimental and Medical Science, Lund University, Lund, Sweden.
Movement Disorders : Official Journal of the Movement Disorder Society
|February 27, 2010
Summary
Gene therapy for Parkinson's disease (PD) is now a reality, with multiple approaches in clinical trials. These therapies aim to alleviate symptoms and potentially modify the disease
Area of Science:
- Neuroscience
- Gene Therapy
- Neurological Disorders
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms.
- Current treatments primarily manage symptoms, with limited disease-modifying options.
Purpose of the Study:
- To review the current landscape of gene therapy approaches for Parkinson's disease.
- To discuss the mechanisms and clinical trial status of various gene therapy strategies.
Main Methods:
- Review of preclinical data and ongoing Phase I/II clinical trials.
- Analysis of gene therapy strategies targeting dopamine production, levodopa enhancement, and basal ganglia circuitry normalization.
Main Results:
- Four distinct gene therapy strategies are in clinical trials for PD.
- Approaches include enhancing dopaminergic function, improving levodopa efficacy, and normalizing brain circuitry.
- Trophic factor gene delivery shows potential for both symptomatic and disease-modifying effects.
Conclusions:
- Gene therapy has transitioned from theoretical concept to clinical reality for Parkinson's disease.
- Multiple gene therapy avenues are being explored for symptomatic relief and potential disease modification in PD patients.
More Related Videos
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
12:13Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
Published on: July 11, 2019
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...